0001209191-17-040610.txt : 20170616 0001209191-17-040610.hdr.sgml : 20170616 20170616174153 ACCESSION NUMBER: 0001209191-17-040610 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170614 FILED AS OF DATE: 20170616 DATE AS OF CHANGE: 20170616 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kite Pharma, Inc. CENTRAL INDEX KEY: 0001510580 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 BUSINESS PHONE: (310) 824-9999 MAIL ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CHAMPSI FARAH CENTRAL INDEX KEY: 0001198321 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36508 FILM NUMBER: 17917029 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-06-14 0 0001510580 Kite Pharma, Inc. KITE 0001198321 CHAMPSI FARAH C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 1 0 0 0 Common Stock 2017-06-14 4 S 0 15000 90.40 D 63664 D Common Stock 2017-06-16 4 S 0 5450 88.11 D 0 I See Footnote The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Reflects the transfer from the reporting person to APVIII of 488 shares of the Issuer's common stock on June 1, 2017. The reporting person has been awarded certain restricted stock units in her capacity as a director of the Company (the "RSUs"), and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein. /s/ David M. Tanen, Attorney-in-Fact 2017-06-16